Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 16, 2025JAMA Pediatrics

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPareeta KotechaWHWenxi HuangYYYu-Liang Yeh

Discussion

Loading...

Member takes

Overview

Systematic review reveals GLP-1 RAs improve glycemic control and weight in youth with obesity or type 2 diabetes, indicating potential benefits.

Key Points

  • GLP-1 RAs significantly reduced HbA1c by -0.44% and body weight by -3.02 kg in children and adolescents.
  • A total of 18 randomized clinical trials included 1402 participants, assessing safety and efficacy outcomes.
  • Systematic review analyzed rates of adverse events like gastrointestinal effects and suicidal ideation across studies.
  • Results suggest major improvements in glycemic and cardiometabolic parameters, though GI AEs require careful monitoring.

Cite This Study

Kotecha et al. (2025) studied this question.

synapsesocial.com/papers/68d42056713b0b5dfea6929bhttps://doi.org/10.1001/jamapediatrics.2025.3243
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 12069-P: Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study2026
  2. 2Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta‐Analysis2025 · 2 citations
  3. 3Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease2025 · 6 citations
  4. 4Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.2025 · 8 citations
  5. 5Cardiovascular and kidney outcomes of <scp>GLP</scp>‐1 receptor agonists in adults with obesity: A target trial emulation study2025 · 11 citations